🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just published! Updated EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma! #mmsm nature.com/articles/s4157… European Hematology Association EMN Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics

onclive.com/view/anito-cel… via @onclive Gurbakhash Kaur presented findings at #EHA2025 #MultipleMyeloma Icahn School of Medicine at Mount Sinai

Now in Blood Cancer Discovery: Largest RW experience with teclistamab ever! Of 509 🇺🇸 pts (88% TEC-1 🙅🏽), ORR 53% and ≥VGPR 45%. mDOR 16 mo if ≥VGPR. I like ≥VGPR focus, i.e. #MMsm M-spike not 0 yet. When occurs, DOR similar for BCMA-naive vs exposed >9 mo ago! aacrjournals.org/bloodcancerdis…

Endless gratitude and joy having the opportunity to share knowledge with myeloma doctors from France, Japan and China. Nothing will stop us from finding the cure ! #mmsm

👇👇👇 Absolutely. T cell redirection is not classical chemotherapy !!!

How Frequently Are Bone Marrow Biopsies Needed in #Myeloma? A Patient’s Guide youtu.be/LdbtHC-CszM?fe… #mmsm Joshua Richter, MD, FACP

Joshua Richter, MD, FACP Luciano J Costa Drake when he finds out that even the consolidation has twice-weekly bortezomib and dex 40 mg weekly…

What do extended MonumenTAL-1 findings mean for real-world treatment in Relapsed-Refractory Multiple Myeloma? In Part 2 of Around the Practice, experts, Ajai Chari, Ajay Nooka, MD, MPH, Muhamed Baljević, MD, FACP, Gurbakhash Kaur, and Anupama Kumar discuss: • Identifying appropriate candidates for

Two specific situations where belantamab can have a major impact are 1) Relapsed high tumor burden myeloma that is refractory to other myeloma drugs and where CART or bispeicifics will be too risky. Here even a few doses of belantamab to control myeloma can open up other

2 negative odac votes for blenrep. I missed the discussion but this drug has a role in myeloma. Hoping the fda still approves it. #mmsm

@KinatSofrim Joshua Richter, MD, FACP SomeoneSomewhere Artur Jurczyszyn agree! always a partnership with pt. FDA cannot decide based on presumed negligence of docs. Many of our meds are difficult. Expertise is important. Wouldn't use this in a pilot or neurosurgeon... every patient unique. But withholding an active/usable drug is counterproductive.

The FDA recently approved linvoseltamab for the treatment of relapsed or refractory multiple #myeloma. Hear Joshua Richter, MD, FACP, of The Tisch Cancer Institute, talk about results of the LINKER-MM1 study that led to FDA approval. ➡️ buff.ly/2gLMfrb

From Adam Kittai and colleagues: International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations ashpublications.org/blood/article/…

Brilliance 👇👇

Legend

Now let’s see what happens here in the US. PDUFA date is today. Blenrep (belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma #mmsm ⁦⁦nizar jacques bahlis⁩ ca.finance.yahoo.com/news/blenrep-b…

Meet the panel: Ajai Chari, Ajay Nooka, MD, MPH, Muhamed Baljević, MD, FACP, Gurbakhash Kaur, and Anupama Kumar—watch as they explore how #Teclistamab and #Elranatamab compare in relapsed/refractory #MultipleMyeloma. In Episode 3 of Around the Practice, they break down efficacy, safety, and clinical

The State of Blenrep: What Patients Should Know - MMRF. New PDUFA for blenrep. October 23. Fingers crossed. #mmsm themmrf.org/mmrf-blogs/the…

📌 Real-world data sheds light on teclistamab use in multiple myeloma patients with renal impairment (RI)—a group often excluded from trials. In 384 patients, 21% had RI (CrCl <40 mL/min), including those on dialysis. 💡 Despite higher cytopenias, efficacy (ORR 52%) and safety

There's still time to register for gotoper.com/courses/live-m… Icahn School of Medicine at Mount Sinai faculty: John Mascarenhas, Joshua Brody, MD, Joshua Richter, MD, FACP